Reserpine-Induced Progressive Parkinsonism in Mice Predisposed and Non-Predisposed to Depressive-Like Behavior


Parkinson’s disease (PD) is a progressive degenerative condition that mainly affects the elderly. The disease comprises motor symptoms such as tremors at rest, loss of voluntary movement, decreased muscle strength, propensity to lean forward and acceleration of the walking pace. These signs are related to the degeneration of the nigrostriatal dopaminergic pathway. Patients also have non-motor symptoms, among which sleep alterations, cognitive deficits, fatigue, pain and depression stand out. Although depression has been described as the most prevalent non-motor symptom, it is not clear whether this mood disorder is due to PD or patients would already have a greater predisposition. The present study evaluated the relationship between the predisposition to depressive-like behavior and the development of motor alterations in a progressive pharmacological model of PD in mice. Mice were classified into groups of depressive-like propensities and submitted to the pharmacological model. Reserpine was administrated at 0.1 mg/kg on alternate days for 40 days. The catalepsy and oral movement tests were used to evaluate motor alterations, the sucrose preference test was used to evaluate anhedonia, and the open field test was applied to evaluate general activity. Reserpine promoted parkinsonian motor impairments, and there were no differences between animals from different depressive-like behavior profiles. Thus, it was not possible to find a relationship between parkinsonism and the propensity to depression based on the basal sucrose preference test. More studies with other evaluations of depressive-like behavior are needed to confirm the results found in our study.

Share and Cite:

Soares, M. , Lopes-Silva, L. , Becegato, M. , Bioni, V. , Lima, A. , Ferreira, G. , Meurer, Y. and Silva, R. (2021) Reserpine-Induced Progressive Parkinsonism in Mice Predisposed and Non-Predisposed to Depressive-Like Behavior. Journal of Behavioral and Brain Science, 11, 267-279. doi: 10.4236/jbbs.2021.1111022.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.


[1] Ascherio, A. and Schwarzschild, M.A. (2016) The Epidemiology of Parkinson’s Disease: Risk Factors and Revention. The Lancet Neurology, 15, 1257-1272.
[2] Berrios, G.E. (2016) Introdução à “Paralisia agitante”, de James Parkinson (1817). Revista Latinoamericana de Psicopatologia Fundamental, 19, 114-121.
[3] Postuma, R.B., Berg, D., Stern, M., Poewe, W., Olanow, W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A.E., Halliday, G., Goetz, C.G., Gasser, T., Dubois, B., Chan, P., Bloem, B.R., Adler, C.H. and Deuschi, G. (2015) MDS Clinical Diagnostic Criteria for Parkinson’s Disease. Movement Disorders, 39, 1591-1599.
[4] Lotharius, J. and Brundin, P. (2002) Pathogenesis of Parkinson’s Disease: Dopamine, Vesicles and Alpha-Synuclein. Nature Reviews Neuroscience, 3, 932-942.
[5] Steidl, E.M.S., Ziegler, J.R. and Ferreira, F.V. (2007) Doença de Parkinson: Revisão Bibliográfica. Disciplinarum Scientia, 8, 115-129.
[6] Cheng, H.C., Ulane, C.M. and Bruke, R.E. (2010) Clinical Progression in Parkinson’s Disease and the Neurobiology of Axons. Annals of Neurology, 67, 715-725.
[7] Schapira, A.H.V., Chaudhuri, K.R. and Jenner, P. (2017) Non-Motor Features of Parkinson Disease. Nature Reviews Neuroscience, 18, 435-450.
[8] Pagonabarraga, J., Kulisevsky, J., Strafella, A.P. and Krack, P. (2015) Apathy in Parkinson’s Disease: Clinical Features, Neural Substrates, Diagnosis, and Treatment. The Lancet Neurology, 14, 528-531.
[9] Pont-Sunyer, C., Hotter, A., Gaig, C., Seppi, K., Compta, Y., Katzenschlager, R., Mas, N., Hofeneder, D., Brücke, T., Bayés, A., Enzel, K., Infante, J., Zach, H., Pirker, W., Posada, I.J., álvarez, R., Ispierto, L., De Fàbregues, O., Callén, A., Palasó, A., Aguilar, M., Martí, M.J., Vallderiola, F., Salamero, M., Poewe, W. and Tolosa, E. (2014) The Onset of Nonmotor Symptoms in Parkinson’s Disease (The ONSET PD Study). Movement Disorders, 30, 229-237.
[10] Martinez-Martin, P., Chaudhuri, K.R., Rojo-Abuin, J.M., Rodriguez-Blazquez, C., Alvarez-Sanchez, M., Arakaki, T., Bergareche-Yarza, A., Chade, A., Garreto, N., Gershanik, O., Kurtis, M.M., Martinez-Castrillo, J.C., Mendoza-Rodriguez, A., Moore, H.P., Rodriguez-Violante, M., Singer, C., Tilley, B.C., Huang, J., Stebbins, G.T. and Goetz, C.G. (2013) Assessing the Non-Motor Symptoms of Parkinson’s Disease: MDS-UPDRS and NMS Scale. European Journal of Neurology, 22, 37-43.
[11] Draoui, A., El Hiba, O., Aimrane, A., El Khiat, A. and Gamrani, H. (2020) Parkinson’s Disease: From Bench to Bedside. Revue Neurologique, 176, 543-559.
[12] Cumming, J.L. (1992) Depression and Parkinson’s Disease: A Review. The American Journal of Psychiatry, 149, 443-454.
[13] Reijnders, J.S.A.M., Ehrt, U., Weber, W.E.J., Aarsland, D. and Leentjens, A.F.G. (2008) A Systematic Review of Prevalence Studies of Depression in Parkinson’s Disease. Movement Disorders, 23, 183-189.
[14] Riedel, O., Heuser, I., Klotsche, J., Dodel, R. and Wittchen, H.U. (2010) Occurrence Risk and Structure of Depression in Parkinson Disease with and without Dementia: Results from GEPAD Study. Journal of Geriatric Psychiatry and Neurology, 23, 27-34.
[15] Nilsson, F.M., Kessing, L.V. Sørensen, T.M., Andersen, P.K. and Bolwig, T.G. (2002) Major Depressive Disorder in Parkinson’s Disease: A Register-Based Study. Acta Psychiatrica Scandinavica, 106, 202-211.
[16] Julien, C.L., Rimes, K.A. and Brown, R.G. (2016) Rumination and Behavioural Factors in Parkinson’s Disease Depression. Journal of Psychosomatic Research, 82, 48-52.
[17] Grover, S., Somaiya, N., Kumar, S. and Avasthi, A. (2015) Psychiatric Aspects of Parkinson’s Disease. Journal of Neurosciences in Rural Practice, 6, 65-76.
[18] Santos, J.R., Cunha, J.A.S., Dierschnabel, A.L., Campêlo, C.L.C., Leão, A.H.F.F., Silva, A.F., Engelberth, R.C.G.J., Izídio, G.S., Cavalcante, J.S., Abílio, V.C., Ribeiro, A.M. and Silva, R.H. (2013) Cognitive, Motor and Tyrosine Hydroxylase Temporal Impairment in a Model of Parkinsionism Induced by Reserpine. Behavioural Brain Research, 253, 68-77.
[19] Leão, A.H., Sarmento-Silva, A.J. and Santos, J.R. (2015) Molecular, Neurochemical, and Behavioral Hallmarkers of Reserpine as a Model for Parkinson’s Disease: New Perspectives to a Long-Standing Model. Brain Pathology, 25, 377-390.
[20] Leão, A.H.F.F., Meurer, Y.S.R., da Silva, A.F., Medeiros, A.M., Campêlo, C.L.C., Abílio, V.C., Engelberth, R.C.G.K., Cavalvante, J.S., Izídio, G.S., Ribeiro, A.M. and Silva, R.H. (2017) Spontaneously Hypertensive Rats (SHR) Are Resistant to a Reserpine-Induced Progressive Model of Parkinson’s Disease: Differences in Motor Behavior, Tyrosine Hydroxylase and α-Synuclein Expression. Frontiers in Aging Neuroscience, 9, Article No. 78.
[21] Fernandes, V.S., Santos, J.R., Leão, A.H., Medeiros, A.M., Melo, T.G., Izídio, G.S., Cabral, A., Ribeiro, R.A., Abílio, V.C., Ribeiro, A.M. and Silva, R.H. (2012) Repeated Treatment with a Low Dose of Reserpine as a Progressive Model of Parkinson’s Disease. Behavior Brain Research, 231, 154-163.
[22] Campêlo, C.L.C., Santos, J.R., Silva, A.F., Dierschnabel, A.L., Pontes, A., Cavalcante, J.S., Ribeiro, A.M. and Silva, R.H. (2017) Exposure to an Enriched Environment Facilitates Motor Recovery and Prevents Short-Term Memory Impairment and Reduction of Stiatal BDNF in a Progressive Pharmacological Model of Parkinsonism in Mice. Behavior Brain Research, 328, 138-148.
[23] Grandi, L.C., Di Giovanni, G. and Galati, A. (2018) Animal Models of Early-Stage Parkinson’s Disease and Acute Dopamine Deficiency to Study Compensatory Neurodegenerative Mechanisms. Journal of Neuroscience Methods, 308, 205-218.
[24] Deumens, R., Blokland, A. and Prickaerts, J. (2002) Modeling Parkinson’s Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway. Experimental Neurology, 175, 303-317.
[25] Schober, A. (2004) Classic Toxin-Induced Animal Models of Parkinson’s Disease: 6-OHDA and MPTP. Cell Tissue Res, 318, 215-224.
[26] Jiang, P.E., Lang, Q.H., Yu, Q.Y., Tang, X.Y., Liu, Q.Q., Li, X.Y. and Feng, X.Z. (2019) Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-Induced Parkinson’s Disease Model. Journal of Visualized Experiments, 7.
[27] Han, Q.W., Yuan, Y.H. and Chen N.H. (2019) The Therapeutic Role of Cannabinoid Receptors and Its Agonists or Antagonists in Parkinson’s Disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 96, Article ID: 109745.
[28] Kaji, Y. and Hirata, K. (2011) Apathy and Anhedonia in Parkinson’s Disease. International Scholarly Research Notices, 2011, Article ID: 219427.
[29] Remy, P., Doder, M., Lees, A., Turjanski, N. and Brooks, D. (2005) Depression in Parkinson’s Disease: Loss of Dopamine and Noradrenaline Innervation in the Limbic System. Brain, 128, 1324-1322.
[30] Cléry-Melin, M., Jollant F. and Gorwood, P. (2018) Reward Systems and Cognitions in Major Depressive Disorder. CNS Spectrums, 24, 64-77.
[31] Dean, J. and Keshavan, M. (2017) The Neurobiology of Depression: An Integrated View. Asian Journal of Psychiatry, 27, 101-111.
[32] Belujon, P. and Grace, A.A. (2017) Dopamine System Dysregulation in Major Depressive Disorders. International Journal of Neuropsychopharmacology, 20, 1036-1046.
[33] Kaminska, K., Lenda, T., Konieczny, J., Czarnecka, A. and Lorenc-Koci, E. (2017) Depressive-Like Neurochemical and Behavioral Markers of Parkinson’s Disease after 6-OHDA Administered Unilaterally to the Rat Medial Forebrain Bundle. Pharmacological Reports, 69, 985-994.
[34] Skalisz, L.L., Beijamini, V., Joca, S.L., Vital, M.A.B.F., Da Cunha, C. and Andreatini, R. (2002) Evaluation of the Face Validity of Reserpine Administration as an Animal Model of Depression-Parkinson’s Disease Association. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 26, 879-883.
[35] Mashour, N.H., Lin, G.I. and Frishman, W.H (1998) Herbal Medicine for the Treatment of Cardiovascular Disease: Clinical Considerations. Archives of Internal Medicine, 158, 2225-2234.
[36] Rejintes, M. and Meyer, P.T. (2019) No Free Lunch with Herbal Preparations: Lessons from a Case of Parkinsonism and Depression Due to Herbal Medicine Containing Reserpine. Frontiers in Neurology, 23, 183-189.
[37] Zhu, G.H., Sun, X.P., Li, J., Pi, L., Tang, H.Q., Gao, H.Q., Cong, H.L., Qu, P., Lu, X.Z., Zhang, X.J., Zhao, L.S., Gui, Y.F., Liu, D.X., Zhang, L.Q., Tang, H., Hu, Y.X., Fan, L. and Hua, Q. (2019) No Association between Low-Dose Reserpine Use and Depression in Older Hypertensive Patient: Result of a Multicenter, Cross-Sectional Study. Journal of Geriatric Cardiology, 16, 608-613.
[38] Baumeister, A.A., Hawkins, M.F. and Uzelac, S.M. (2003) The Myth of Reserpine-Induced Depression: Role in the Historical Development of the Monoamine Hypothesis. Journal of the History of the Neurosciences, 12, 207-220.
[39] Lemieux, G., Davignon, A. and Genest, J. (1956) Depressive States during Rauwolfia Therapy for Arterial Hypertension: A Report of 30 Cases. Canadian Medical Association Journal, 74, 522-526.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.